Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06599684 · ClinicalTrials.gov registry record · Phase 2
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
A Phase 2 study, sponsored by Invirsa.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT06599684 is a Phase 2 study that has completed, run by Invirsa. The registered enrollment target is 19 participants.
The verdict
NCT06599684, a Phase 2 study, has completed, sponsored by Invirsa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR \[Part 1\] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR \[Part 2\].
Interventions
- DRUG INV-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-09-07 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06599684
The ClinicalTrials.gov registry entry for NCT06599684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invirsa, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INV-102 is the first listed.
NCT06599684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06599684 about?
NCT06599684 is a clinical study titled "Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy". Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR \[Part 1\] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR \[P...
What is the current status of trial NCT06599684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2024-09-07. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT06599684?
The interventions under investigation include: INV-102 (DRUG).
Who is sponsoring clinical trial NCT06599684?
This trial is sponsored by Invirsa, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.